GR3035774T3 - Substituted benzolactam compounds as substance p antagonists - Google Patents
Substituted benzolactam compounds as substance p antagonistsInfo
- Publication number
- GR3035774T3 GR3035774T3 GR20010400624T GR20010400624T GR3035774T3 GR 3035774 T3 GR3035774 T3 GR 3035774T3 GR 20010400624 T GR20010400624 T GR 20010400624T GR 20010400624 T GR20010400624 T GR 20010400624T GR 3035774 T3 GR3035774 T3 GR 3035774T3
- Authority
- GR
- Greece
- Prior art keywords
- substance
- antagonists
- compounds
- benzolactam compounds
- substituted benzolactam
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9501359 | 1995-07-07 | ||
| PCT/IB1996/000434 WO1997003066A1 (en) | 1995-07-07 | 1996-05-09 | Substituted benzolactam compounds as substance p antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3035774T3 true GR3035774T3 (en) | 2001-07-31 |
Family
ID=14126073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010400624T GR3035774T3 (en) | 1995-07-07 | 2001-04-20 | Substituted benzolactam compounds as substance p antagonists |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6180647B1 (el) |
| EP (1) | EP0840732B1 (el) |
| JP (1) | JP3042894B2 (el) |
| AT (1) | ATE199552T1 (el) |
| CA (1) | CA2226292C (el) |
| DE (1) | DE69612003T2 (el) |
| DK (1) | DK0840732T3 (el) |
| ES (1) | ES2155601T3 (el) |
| GR (1) | GR3035774T3 (el) |
| MX (1) | MX9800187A (el) |
| WO (1) | WO1997003066A1 (el) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9706196A (es) * | 1996-08-14 | 1998-02-28 | Pfizer | Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p. |
| TW436483B (en) * | 1997-08-19 | 2001-05-28 | Otsuka Pharma Co Ltd | Carbostyril derivatives, process for their preparation and pharmaceutical composition or cosmetic composition for inhibiting skin erythema and/or skin pigmentation |
| TW426667B (en) * | 1997-11-19 | 2001-03-21 | Pfizer | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists |
| CZ20013977A3 (cs) * | 1999-05-06 | 2003-10-15 | Pfizer Products Inc. | Substituované benzolaktamové sloučeniny |
| RS49964B (sr) | 1999-05-17 | 2008-09-29 | Pfizer Products Inc., | Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli |
| IL145949A0 (en) * | 1999-05-21 | 2002-07-25 | Pfizer Prod Inc | 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| ES2211455T3 (es) * | 1999-10-18 | 2004-07-16 | Pfizer Products Inc. | Procedimiento para la preparacion de compuestos eteres ciclicos piperidinilaminometil trifluorometilicos. |
| CA2324116A1 (en) * | 1999-10-25 | 2001-04-25 | Susan Beth Sobolov-Jaynes | Nk-1 receptor antagonists and eletriptan for the treatment of migraine |
| US7119207B2 (en) | 2000-04-10 | 2006-10-10 | Pfizer Inc | Benzoamide piperidine containing compounds and related compounds |
| WO2001077100A2 (en) * | 2000-04-10 | 2001-10-18 | Pfizer Products Inc. | Benzoamide piperidine compounds as substance p antagonists |
| US20020049211A1 (en) * | 2000-09-06 | 2002-04-25 | Sobolov-Jaynes Susan Beth | Combination treatment for depression and anxiety |
| EP1192952A3 (en) * | 2000-09-28 | 2003-03-26 | Pfizer Products Inc. | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist |
| EP1345603A4 (en) * | 2000-12-20 | 2004-09-08 | Merck & Co Inc | P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL |
| GB0108982D0 (en) | 2001-04-10 | 2001-05-30 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003233244B2 (en) * | 2002-06-07 | 2010-05-20 | Cortical Pty Ltd | Therapeutic molecules and methods-1 |
| WO2004036461A2 (en) * | 2002-10-14 | 2004-04-29 | Battelle Memorial Institute | Information reservoir |
| US7514466B2 (en) | 2004-04-27 | 2009-04-07 | Wyeth | Purification of progesterone receptor modulators |
| ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| ES2382814T3 (es) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer |
| EP1904069B1 (en) | 2005-07-15 | 2018-06-13 | Albany Molecular Research, Inc. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US20090197878A1 (en) * | 2008-02-01 | 2009-08-06 | Wyeth | SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR |
| US8598184B2 (en) | 2008-03-03 | 2013-12-03 | Tiger Pharmatech | Protein kinase inhibitors |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CA2760837C (en) | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| KR20120034644A (ko) | 2009-05-12 | 2012-04-12 | 알바니 몰레큘라 리써치, 인크. | 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도 |
| WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| MX363243B (es) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Composiciones para tratar cáncer y usos de dichas composiciones. |
| RU2690663C2 (ru) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Замещенные имидазопиридины в качестве ингибиторов hdm2 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | PRMT5 INHIBITORS |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680283A (en) | 1984-09-26 | 1987-07-14 | Merck & Co., Inc. | Analogs of substance P and eledoisin |
| MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| WO1994013663A1 (en) * | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
-
1996
- 1996-05-09 JP JP9505628A patent/JP3042894B2/ja not_active Expired - Fee Related
- 1996-05-09 ES ES96911079T patent/ES2155601T3/es not_active Expired - Lifetime
- 1996-05-09 EP EP96911079A patent/EP0840732B1/en not_active Expired - Lifetime
- 1996-05-09 MX MX9800187A patent/MX9800187A/es not_active IP Right Cessation
- 1996-05-09 DK DK96911079T patent/DK0840732T3/da active
- 1996-05-09 DE DE69612003T patent/DE69612003T2/de not_active Expired - Fee Related
- 1996-05-09 CA CA002226292A patent/CA2226292C/en not_active Expired - Fee Related
- 1996-05-09 AT AT96911079T patent/ATE199552T1/de not_active IP Right Cessation
- 1996-05-09 US US08/983,004 patent/US6180647B1/en not_active Expired - Fee Related
- 1996-05-09 WO PCT/IB1996/000434 patent/WO1997003066A1/en active IP Right Grant
-
2001
- 2001-04-20 GR GR20010400624T patent/GR3035774T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2226292C (en) | 2001-12-11 |
| DK0840732T3 (da) | 2001-04-17 |
| DE69612003T2 (de) | 2001-06-21 |
| EP0840732B1 (en) | 2001-03-07 |
| JP3042894B2 (ja) | 2000-05-22 |
| CA2226292A1 (en) | 1997-01-30 |
| ATE199552T1 (de) | 2001-03-15 |
| DE69612003D1 (de) | 2001-04-12 |
| ES2155601T3 (es) | 2001-05-16 |
| US6180647B1 (en) | 2001-01-30 |
| JPH11502861A (ja) | 1999-03-09 |
| MX9800187A (es) | 1998-05-31 |
| WO1997003066A1 (en) | 1997-01-30 |
| EP0840732A1 (en) | 1998-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3035774T3 (en) | Substituted benzolactam compounds as substance p antagonists | |
| MY132322A (en) | Methods for inhibiting bone loss | |
| ZA951107B (en) | Substituted spiro compounds for the treatment of inflammation | |
| BG106340A (en) | Substituted oxoazaheterocyclyl compounds | |
| UA34466C2 (uk) | Засіб для несистемної боротьби з паразитуючими комахами | |
| HK1040397A1 (en) | substituted benzopyran analogs for the treatment of inflammation. | |
| NZ332780A (en) | Substituted amines for the treatment of neurological and neuropsychiatric disorders | |
| ES2080297T3 (es) | Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos. | |
| MX9805253A (es) | Antagonistas del receptor de vitronectina. | |
| EP0760658A4 (en) | COMPOUNDS INHIBITOR OF OSTEOCLASTE INDUCED BONE RESORPTION | |
| AP9801312A0 (en) | 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist. | |
| HU9603584D0 (en) | Sterol derivatives which applicable for regulation of meiosis | |
| CY2538B1 (en) | Tetrahydropyrido compounds | |
| MX9801190A (es) | Inhibidores de prolil endopeptidasa. | |
| GB9611614D0 (en) | Process for inhibiting the effect of flourescent whitening agents | |
| ATE226071T1 (de) | Antikonvulsive derivate zur behandlung von neuropathischem schmerz | |
| FI980091A0 (fi) | Menetelmä ylijäämäaktiivilietteen käsittelemiseksi | |
| IL113057A0 (en) | Compositions for the treatment of dandruff | |
| GB9510162D0 (en) | Compositions for the treatment of skin conditions | |
| GR3032175T3 (en) | IMPROVED SYSTEM FOR THE TRANSDERMAL APPLICATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS AT CONTROLLED pH. | |
| CA2294243A1 (en) | Novel cyanoaziridines for treating cancer | |
| ATE204167T1 (de) | Antikonvulsive derivate zur behandlung von psoriasis | |
| EP1135141A4 (en) | PHOSPHOLIPASE INHIBITORS FOR TREATING CANCER | |
| FR2708203B1 (fr) | Procédé d'inhibition de la perception des odeurs. | |
| UA31995A (uk) | Засіб для профілактики і лікування гіпогалактії |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |